The founders of Savant HWP Inc. believe they have identified a molecule that could prove effective in treating many kinds of substance as well as behavioral addictions, because it appears to influence relevant brain chemistry at a fundamental level. Its compound binds to the alpha-3-beta-4 nicotinic acetylcholine receptor and appears to indirectly regulate production of dopamine in the mid-brain.
Private Company Edition: Hatteras Venture Partners now has more than $900m under management. Also, in recent $100m-plus VC rounds, Strand Therapeutics raised a $153m series A, ARTBIO revealed a $132m series B and Minghui Pharmaceutical secured a $131m pre-IPO round.
The first new drug for fibromyalgia since 2009, Tonyma is a reformulation of cyclobenzaprine intended for chronic therapy. Tonix said the drug targets non-restorative sleep.
The drugmaker announced the launch of an at-home version of its nasal FluMist vaccine, as more companies are looking into direct-to-patient drug sales in response to Trump’s most favored nation pricing proposals.